kallidin, des-arg(10)- has been researched along with sb 203580 in 1 studies
Studies (kallidin, des-arg(10)-) | Trials (kallidin, des-arg(10)-) | Recent Studies (post-2010) (kallidin, des-arg(10)-) | Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) |
---|---|---|---|---|---|
80 | 4 | 17 | 3,489 | 4 | 1,137 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, A; Fox, A; Ganju, P; Núñez, X; Patel, S | 1 |
1 other study(ies) available for kallidin, des-arg(10)- and sb 203580
Article | Year |
---|---|
p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia.
Topics: Animals; Cell Line; Cyclooxygenase 2; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hindlimb; Humans; Hyperalgesia; Imidazoles; Inflammation; Interleukin-1; Isoenzymes; Kallidin; Male; Membrane Proteins; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B1; Receptors, Bradykinin; Tumor Necrosis Factor-alpha | 2001 |